73
Participants
Start Date
October 3, 2016
Primary Completion Date
June 19, 2019
Study Completion Date
December 31, 2020
osilodrostat
In the form of filmcoated tablets for oral administration, in the following dose strengths: 1 mg, 5 mg, 10 mg, and 20 mg.
osilodrostat Placebo
Matching Placebo in the form of filmcoated tablets for oral administration
Novartis Investigative Site, Leuven
Novartis Investigative Site, Lucerne
Columbia University Medical Center New York Presbyterian Neuroendocrine Unit, New York
Memorial Sloan Kettering Cancer Center, New York
Novartis Investigative Site, Bangkok
Novartis Investigative Site, Bangkok
Novartis Investigative Site, A Coruña
University of Pennsylvania Medical Center University of Pennsylvania, Philadelphia
Novartis Investigative Site, Madrid
Novartis Investigative Site, Málaga
Novartis Investigative Site, Istanbul
Novartis Investigative Site, Seville
Novartis Investigative Site, Kocaeli
Novartis Investigative Site, Valencia
Novartis Investigative Site, Alzira
University of Michigan Comprehensive Cancer Center, Ann Arbor
University of Colorado Endocrinology Clinical Trials Unit, Aurora
Oregon Health and Science University SC LCI699C2301, Portland
Novartis Investigative Site, Beijing
Novartis Investigative Site, Beijing
Novartis Investigative Site, Moscow
Novartis Investigative Site, Guangzhou
Novartis Investigative Site, Chengdu
Novartis Investigative Site, Fortaleza
Novartis Investigative Site, Rio de Janeiro
Novartis Investigative Site, São Paulo
Novartis Investigative Site, São Paulo
Novartis Investigative Site, Halifax
Novartis Investigative Site, Montreal
Novartis Investigative Site, Sherbrooke
Novartis Investigative Site, San Pedro
Novartis Investigative Site, Athens
Novartis Investigative Site, Warsaw
Novartis Investigative Site, Krakow
Novartis Investigative Site, Warsaw
Novartis Investigative Site, Porto
Lead Sponsor
Novartis Pharmaceuticals
INDUSTRY